Skip to main content
SpringerLink
Log in

Hypermethylation status of E-cadherin and p16INK4a in gastrointestinal stromal tumor

  • Published:
Chinese Journal of Cancer Research

Abstract

Objective

To investigate the methylation status of CpG island in E-cadherin(CDH 1 ), P16INK4a(P16) promoter region,and to analyze their role in gastrointestinal stromal tumor (GISTs).

Methods

A total of 56 surgically resected GISTs were obtained from January 2003 to December 2005. The routine H&E-stained sections and CD117, CD34-immunoreactions were reviewed to verify the morphologic diagnosis. Methylation status of the CDH 1 , P16INK4a promoter region was analyzed by methylation specific polymerase chain reaction (MSP) from chemically modified DNA after Na-bisulfite treatment.

Results

The frequency of CDH 1 gene methylation was 32% (18 of 56) in GISTs. The rate was 9% (1 of 11), 21% (4 of 19), 41.6% (5 of 12), and 57% (8 of 14) for very low risk, low risk, intermediate risk, and high risk GISTs; P16 INK4a methylation was found in 19 of 56(34%) cases. The rate was 0% (0 of 11), 16% (3 of 19), 50% (6 of 12), and 71% (10 of 14) for very low risk, low risk, intermediate risk, and high risk GISTs. Statistical analysis indicated that of the 56 cases, there was significant association of CDH 1 and/or P16 INK4a methylation status with tumor malignant behavior (methylation rate 23/56, 41%, P<0.01) and site (P<0.05).

Conclusion

E-cadherin (CDH 1 ) and/or P16 INK4a promoter hypermethylation is strongly associated with risk grade, may be a useful biomarker for GISTs risk assessment, and may shed light on new therapeutic options to treat GISTs

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up[J]. Am J Surg Pathol 2005; 29:52–68.

    Article  PubMed  Google Scholar 

  2. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34[J]. Mod Pathol 1998; 11:728–734.

    PubMed  CAS  Google Scholar 

  3. Emory TS, Sobin LH, Lukes L, et al. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site[J]. Am J Surg Pathol 1999; 23:82–87.

    Article  PubMed  CAS  Google Scholar 

  4. Franquemont DW. Differentiation and risk assessment of gastrointestinal stromal tumors[J]. Am J Clin Pathol 1995; 103:41–47.

    PubMed  CAS  Google Scholar 

  5. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach[J]. Int J Surg Pathol 2002; 10:81–89.

    PubMed  Google Scholar 

  6. O’leary T, Berman JJ. Gastrointestinal stromal tumors: answers and questions[J]. Hum Pathol 2002; 33:456–458.

    Article  PubMed  Google Scholar 

  7. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach[J]. Hum Pathol 2002; 33:459–465.

    Article  PubMed  Google Scholar 

  8. Christofori G, Semb H. The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene[J]. Trends Biochem Sci 1999; 24:73–76.

    Article  PubMed  CAS  Google Scholar 

  9. Graziano F, Humar B, Guilford P. The role of the E-cadherin gene (CDH1) in diffuse gastrie cancer susceptibility: from the laboratory to clinical practice[J]. Ann Oncol 2003; 14:1705–1713.

    Article  PubMed  CAS  Google Scholar 

  10. Debiec-Rychter M, Lasota J, Sarlomo-Rikala M, et al. Chromosomal aberrations in malignant gastrointestinal stromal tumors: correlation with c-KIT gene mutation[J]. Cancer Genet Cytogenet 2001; 128:24–30.

    Article  PubMed  CAS  Google Scholar 

  11. El-Rifai W, Sarlomo-Rikala M, Andersson LC, et al. DNA sequence copy number changes in gastrointestinal stromal tumors: tumor progression and prognostic significance[J]. Cancer Res 2000; 60:3899–3903.

    PubMed  CAS  Google Scholar 

  12. Berman J, O’Leary TJ. Gastrointestinal stromal tumor workshop[J]. Hum Pathol 2001; 32:578–582.

    Article  PubMed  CAS  Google Scholar 

  13. Jones PA, Buckley JD. The role of DNA methylation in cancer[J]. Adv Cancer Res 1990; 54:1–23.

    Article  PubMed  CAS  Google Scholar 

  14. Graziano F, Arduini F, Ruzzo A, et al. Combined analysis of E-cadherin gene (CDH1) promoter hypermethylation and E-cadherin protein expression in patients with gastric cancer: implications for treatment with demethylating drugs[J]. Ann Oncol 2004; 15:489–492.

    Article  PubMed  CAS  Google Scholar 

  15. Ricci R, Arena V, Castri F, Martini M, et al. Role of p16/INK4a in gastrointestinal stromal tumor progression[J]. Am J Clin Pathol 2004; 122:35–43.

    Article  PubMed  CAS  Google Scholar 

  16. Kim BN, Yamamoto H, Ikeda K, et al. Methylation and expression of p16INK4 tumor suppressor gene in primary colorectal cancer tissues[J]. Int J Oncol 2005; 26:1217–1226.

    PubMed  CAS  Google Scholar 

  17. Esteller M, Sanchez-Cespedes M, Rosell R, et al. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients[J]. Cancer Res 1999; 59:67–70.

    PubMed  CAS  Google Scholar 

  18. Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands[J]. Proc Natl Acad Sci USA 1996; 93:9821–9826.

    Article  PubMed  CAS  Google Scholar 

  19. Tamura G, Yin J, Wang S, Fleisher AS, et al. E-Cadherin gene promoter hypermethylation in primary human gastric carcinomas[J]. J Natl Cancer Inst 2000; 92:569–573.

    Article  PubMed  CAS  Google Scholar 

  20. Caca K, Feisthammel J, Klee K, et al. Inactivation of the INK4a/ARF locus and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cell lines[J]. Int J Cancer 2002; 97:481–488.

    Article  PubMed  CAS  Google Scholar 

  21. Ueki T, Toyota M, Skinner H, et al. Identification and characterization of differentially methylated CpG islands in pancreatic carcinoma[J]. Cancer Res 2001; 61:8540–8546.

    PubMed  CAS  Google Scholar 

  22. Lee S, Lee HJ, Kim JH, et al. Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis[J]. Am J Pathol 2003; 163:1371–1378.

    PubMed  CAS  Google Scholar 

  23. House MG, Guo M, Efron DT, et al. Tumor suppressor gene hypermethylation as a predictor of gastric stromal tumor behavior[J]. J Gastrointest Surg 2003; 7:1004–1014.

    Article  PubMed  Google Scholar 

  24. Ramchandani S, Bhattacharya SK, Cervoni N, Szyf M. DNA methylation is a reversible biological signal[J]. Proc Natl Acad Sci USA 1999; 96:6107–6112.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China

    Liang Jian-fang  (梁建芳)

Authors
  1. Liang Jian-fang  (梁建芳)
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Liang Jian-fang  (梁建芳).

Additional information

Foundation item: This work was supported by the Natural Science Foundation of Shanxi Province (No. 2006011122).

Biography: LIANG Jian-fang (1959–), female, associate professor, candidate for doctor of medicine, Tongji Medical College, majors in Pathology.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liang, Jf. Hypermethylation status of E-cadherin and p16INK4a in gastrointestinal stromal tumor. Chin. J. Cancer Res. 18, 270–275 (2006). https://doi.org/10.1007/s11670-006-0270-z

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11670-006-0270-z

Key words

CLC number

Search

Navigation